<DOC>
	<DOC>NCT01328002</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.</brief_summary>
	<brief_title>Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia</brief_title>
	<detailed_description>- 8 weeks open-label milnacipran period - Followed by randomization to 8-weeks double blind treatment period for eligible patients</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Diagnosis of primary fibromyalgia 1317 years of age Severe psychiatric illness Severe renal impairment Evidence of active liver disease Pregnant or breastfeeding Significant risk of suicidality Unable, unwilling or unadvisable to discontinue prohibited medications</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Pediatric Fibromyalgia</keyword>
	<keyword>Adolescent Fibromyalgia</keyword>
	<keyword>milnacipran</keyword>
	<keyword>Savella</keyword>
	<keyword>loss of therapeutic response</keyword>
	<keyword>Forest Research Institute</keyword>
	<keyword>Pain</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Serotonin Norepinephrine Reuptake Inhibitors</keyword>
	<keyword>Randomized Withdrawal</keyword>
</DOC>